NCT01858545

Brief Summary

The primary objective of this study is to assess the effectiveness of MatriStem devices compared to cellular dermal replacement tissue, for the treatment of non-healing diabetic foot ulcers.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2013

Typical duration for not_applicable

Geographic Reach
1 country

9 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

May 17, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 21, 2013

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
2.3 years until next milestone

Results Posted

Study results publicly available

March 29, 2018

Completed
Last Updated

April 15, 2021

Status Verified

March 1, 2021

Enrollment Period

2.6 years

First QC Date

May 17, 2013

Results QC Date

February 27, 2018

Last Update Submit

March 19, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Complete Wound Closure

    Number of participants with incidence of complete wound closure

    8 Weeks

Study Arms (2)

Experimental

EXPERIMENTAL

MatriStem MicroMatrix and MatriStem Wound Matrix

Device: MatriStem

Comparator

ACTIVE COMPARATOR

Cellular Dermal Replacement Tissue

Device: Cellular Dermal Replacement Tissue

Interventions

MatriStemDEVICE

MatriStem MicroMatrix and MatriStem Wound Matrix

Experimental

Cellular Dermal Replacement Tissue

Comparator

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject has a current diagnosis of type I or type II diabetes
  • Subject's ulcer is on the forefoot or heel
  • Subject has chronic ulcer - has been present for minimum of 4 weeks
  • Subject's ulcer extends through the dermis and into the subcutaneous tissue
  • Subject's HgbA1c \<12%
  • Subject has adequate circulation to the study foot as evidenced by a Doppler measured ABI greater than or equal to 0.7after 10 minutes rest

You may not qualify if:

  • Subject has a known sensitivity to bovine- or porcine-derived products.
  • Subject's ulcer is due to a non-diabetic etiology
  • Subject's ulcer is over a Charcot deformity of the mid-foot
  • Subject's random blood sugar readings are \>450 mg/dL
  • Subject is on dialysis
  • Subject has a non-study ulcer on the study limb located within 7.0 cm of the study ulcer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Carl t. Hayden Phoenix VA Medical Center

Phoenix, Arizona, 85012, United States

Location

Associated Foot & Ankle Specialists, PC

Phoenix, Arizona, 85015, United States

Location

Center for Clinical Research Inc.

Castro Valley, California, 94546, United States

Location

Valley Vascular Surgery Associates

Fresno, California, 93720, United States

Location

Denver VA Medical Center

Denver, Colorado, 80220, United States

Location

Georgetown University Medical Center

Washington D.C., District of Columbia, 20007, United States

Location

Advanced Research Institute of Miami

Homestead, Florida, 33030, United States

Location

NewPhase Clinical Trials, Corp.

Miami Beach, Florida, 33140, United States

Location

Professional Health Care of Pinellas

St. Petersburg, Florida, 33713, United States

Location

MeSH Terms

Conditions

Diabetic Foot

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Results Point of Contact

Title
Manager, Clinical Research
Organization
Integra LifeSciences

Study Officials

  • Thomas Gilbert, PhD

    Integra LifeSciences

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2013

First Posted

May 21, 2013

Study Start

May 1, 2013

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

April 15, 2021

Results First Posted

March 29, 2018

Record last verified: 2021-03

Locations